Eli Lilly has outpaced Ozempic-maker Novo Nordisk in the race to develop new incretin drugs. The company is set to capture 50% of the $95 billion obesity market by 2050. We got a glimpse into Eli ...

And amid all that, Eli Lilly continues to grow its revenue at a faster pace than any of its comparable peers. In the first quarter, the company's revenue jumped by 45% year over year to $12.7 billion.

Novo Nordisk's stock is down, the CEO is out, and Eli Lilly is ascendant. Danish drugmaker projects confidence, but R&D veterans say caution carried a cost.

Eli Lilly (NYSE: LLY) reported its Q1 2025 earnings a few weeks ago, and it was said to have achieved an accelerated growth in revenue of 45% to $12.73 billion.

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on my Strong Buy rating for LLY.

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin drug strategy.